Moderna Says mRNA Flu Vaccine Sailed Through Trial, Beating Standard Shot

Moderna's mRNA-based seasonal flu vaccine proved 27% more effective at preventing influenza infections than standard flu shots in a Phase 3 trial involving nearly 41,000 people aged 50 and above, the firm said this week. The company announced that mRNA-1010 had an overall vaccine efficacy that was 26.6% higher than conventional shots, rising to 27.4% higher in participants aged 65 and older during the six-month study period. The 2024-2025 flu season hospitalized an estimated 770,000 Americans, according to the Centers for Disease Control and Prevention.

Read more of this story at Slashdot.